Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Antimicrobial resistance (AMR) represents a global health crisis, responsible for millions of deaths worldwide and posing an existential threat to our ...

A new strategy has been developed to prevent and treat tuberculosis using antigen-presenting cells. Professor Shin Sung-jae and Dr. Kim Hong-min's research team at Yonsei University Medical School ...

Health and Human Services Secretary Robert F. Kennedy Jr. is targeting the government’s Vaccine Injury Compensation Program, without which manufacturers might cease producing shots. (Eric ...

WASHINGTON — The Department of Health and Human Services will cancel contracts and pull funding for some vaccines that are being developed to fight respiratory viruses like COVID-19 and the flu.

Invivyd, Inc. has submitted a Citizen Petition to the FDA advocating for a new approach to the development of COVID-19 vaccines and monoclonal antibodies (mAbs) to restore public trust in health ...

The search for vaccines to fight poliomyelitis started in the 1920s, but it wasn't until the 1950s that the search bore fruit with the introduction of two vaccines. The first was the Salk inactivated ...

LYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced the successful ...